Stockholders Equity and StockBased Compensation (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
|---|
| Stockholders Equity and Stock-Based Compensation |
|
| Schedule Of Share-based Compensation, Stock Options, Activity |
|
|
2022 |
|
2021 |
|
Expected volatility |
|
97.58% to 115.37% |
|
95.15% to 131.85% |
|
Risk free interest rate |
|
1.02% to 3.28% |
|
0.06% to 0.93% |
|
Dividend yield rate |
|
0 |
|
0 |
|
Weighted average years |
|
2-6 years |
|
1-6 years |
|
Closing price per share - common stock |
|
$5.93 to $6.27 |
|
$4.55 to $6.51 |
|
|
| Schedule Of Stock Option Transactions Of The Employees |
|
|
Options
Outstanding
|
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Grant Date
Fair Value
|
|
Beginning of the year - January 1, 2022 |
|
|
538,713 |
|
|
$ |
18.51 |
|
|
$ |
12.92 |
|
Granted |
|
|
18,852 |
|
|
|
6.17 |
|
|
|
3.98 |
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Forfeited |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Expired |
|
|
(31,662 |
) |
|
|
7.29 |
|
|
|
2.37 |
|
End of the period - December 31, 2022 |
|
|
525,903 |
|
|
$ |
18.74 |
|
|
$ |
13.23 |
|
Options exercisable |
|
|
514,513 |
|
|
$ |
19.03 |
|
|
$ |
13.43 |
|
|
|
Options
Outstanding
|
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Grant Date
Fair Value
|
|
Beginning of the year - January 1, 2021 |
|
|
515,847 |
|
|
$ |
20.23 |
|
|
$ |
14.51 |
|
Granted |
|
|
58,164 |
|
|
|
6.72 |
|
|
|
2.58 |
|
Exercised |
|
|
(30,282 |
) |
|
|
8.94 |
|
|
|
6.77 |
|
Forfeited |
|
|
(3,997 |
) |
|
|
62.52 |
|
|
|
43.63 |
|
Expired |
|
|
(1,019 |
) |
|
|
329.81 |
|
|
|
291.73 |
|
End of the year - December 31, 2021 |
|
|
538,713 |
|
|
$ |
18.51 |
|
|
$ |
12.92 |
|
Options exercisable |
|
|
526,947 |
|
|
$ |
18.79 |
|
|
$ |
13.11 |
|
|
| Schedule Of Non-vested Options, Activity |
|
|
Shares |
|
|
Weighted Average Exercise Price |
|
|
Weighted Average Fair Value
Grant Date
|
|
Non-vested - December 31, 2020 |
|
|
49,726 |
|
|
$ |
9.71 |
|
|
$ |
7.44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
58,164 |
|
|
|
6.72 |
|
|
|
2.58 |
|
Vested |
|
|
(96,124 |
) |
|
|
8.40 |
|
|
|
4.89 |
|
Forfeited |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Non-vested - December 31, 2021 |
|
|
11,766 |
|
|
$ |
5.71 |
|
|
$ |
4.25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
18,852 |
|
|
|
6.17 |
|
|
|
3.98 |
|
Vested |
|
|
(19,228 |
) |
|
|
6.17 |
|
|
|
3.90 |
|
Forfeited |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Non-vested - December 31, 2022 |
|
|
11,390 |
|
|
$ |
5.69 |
|
|
$ |
4.39 |
|
|
| Schedule Of Stock Options Exercisable |
|
|
|
Stock Options Outstanding |
|
|
Stock Options Vested |
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
Remaining |
|
|
|
|
|
Weighted |
|
|
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
Contractual |
|
|
Number |
|
|
Average |
|
|
Exercise |
|
Life |
|
|
of |
|
|
Exercise |
|
|
Life |
|
|
of |
|
|
Exercise |
|
|
Prices |
|
-Years |
|
|
Awards |
|
|
Price |
|
|
-Years |
|
|
Awards |
|
|
Price |
|
$ |
3.82-$9.00 |
|
|
5.44 |
|
|
|
128,407 |
|
|
$ |
4.81 |
|
|
|
5.10 |
|
|
|
117,017 |
|
|
$ |
4.72 |
|
$ |
9.01-$12.48 |
|
|
5.60 |
|
|
|
116,544 |
|
|
$ |
10.80 |
|
|
|
5.60 |
|
|
|
116,544 |
|
|
$ |
10.80 |
|
$ |
12.49-$24.00 |
|
|
4.12 |
|
|
|
195,090 |
|
|
$ |
14.23 |
|
|
|
4.12 |
|
|
|
195,090 |
|
|
$ |
14.23 |
|
$ |
24.01-$72.00 |
|
|
2.72 |
|
|
|
62,771 |
|
|
$ |
55.07 |
|
|
|
2.72 |
|
|
|
62,771 |
|
|
$ |
55.07 |
|
$ |
72.01-$75.60 |
|
|
2.15 |
|
|
|
23,091 |
|
|
$ |
75.59 |
|
|
|
2.15 |
|
|
|
23,091 |
|
|
$ |
75.59 |
|
|
Total |
|
|
4.52 |
|
|
|
525,903 |
|
|
$ |
18.74 |
|
|
|
4.42 |
|
|
|
514,513 |
|
|
$ |
19.03 |
|
|
| Schedule vesting for outstanding RSA |
|
|
|
|
|
Weighted |
|
|
|
Number |
|
|
Average |
|
|
|
of |
|
|
Grant Date |
|
|
|
Shares |
|
|
Fair Value |
|
Total RSUs outstanding at January 1, 2021 |
|
|
243,800 |
|
|
$ |
2.69 |
|
Total RSUs granted |
|
|
— |
|
|
$ |
— |
|
Total RSUs vested (including accelerated vesting) |
|
|
(235,850 |
) |
|
$ |
2.69 |
|
Total RSUs forfeited |
|
|
(7,950 |
) |
|
$ |
2.69 |
|
Total unvested RSUs outstanding at December 31, 2021 |
|
|
— |
|
|
$ |
— |
|
|
|
|
|
|
Weighted |
|
|
|
Number |
|
|
Average |
|
|
|
of |
|
|
Grant Date |
|
|
|
Shares |
|
|
Fair Value |
|
Total RSAs outstanding at January 1, 2022 |
|
|
377,176 |
|
|
$ |
10.69 |
|
Total RSAs granted |
|
|
290,590 |
|
|
$ |
4.71 |
|
Total RSAs vested |
|
|
(62,862 |
) |
|
$ |
10.69 |
|
Total performance-based RSAs expired |
|
|
(188,588 |
) |
|
$ |
10.69 |
|
Total unvested RSAs outstanding at December 31, 2022 |
|
|
416,316 |
|
|
$ |
6.52 |
|
|
|
Year Ending December 31, |
|
|
|
2023 |
|
|
2024 |
|
|
2025 |
|
|
Total |
|
Scheduled vesting |
|
|
159,727 |
|
|
|
159,726 |
|
|
|
96,863 |
|
|
|
416,316 |
|
|
| Schedule Of Stock Based Compensation Expense |
|
|
Years Ended |
|
|
|
December 31, |
|
|
|
2022 |
|
|
2021 |
|
Research and development expenses |
|
$ |
— |
|
|
$ |
— |
|
General and administrative expenses |
|
|
0.8 |
|
|
|
0.8 |
|
Total stock-based compensation expense |
|
$ |
0.8 |
|
|
$ |
0.8 |
|
|